MOLOGIC - Key Persons
A US national who came to the UK in 2008, Chris has 25 years' success in bringing new medical products from concept to market adoption in VC and Fortune 500 companies, raising over $50M funding from investors. Previously CEO of GlySure, Chris is currently chairman of Elasmogen, and non-executive director for MediSieve, Causeway Therapeutics, Deltex Medical, and Health Enterprise East
- Director of Epidemics and Neglected Tropical Diseases
Emily oversees the Epidemics and Neglected Tropical Diseases portfolio, a key focus area for Global Access Diagnostics in its vision for improved global health. Emily is a Reader and Head of Group at the Liverpool School of Tropical Medicine, where she runs the diagnostics unit and organises large clinical evaluations, instrumental in the COVID-19 pandemic. Previously, Emily worked at the Royal Tropical Institute in the Netherlands and has a PhD from Bristol University focusing on diagnostic development for parasitic disease.
- INVESTMENT MANAGER
- Chief Executive Officer
- Co - Founder
Mark has over 20 years' experience in R&D, sales, marketing and management of life science and diagnostic companies. With experience gained in both large-cap and start-up companies, covering everything from benchwork to sales and technical support, Mark co-founded Mologic Ltd in 2003.
- Chief Scientific Officer
- Co - Founder
Paul has worked in immunology for 45 years and has founded or co-founded eight bioscience businesses since 2002, with Mologic being the most prominent. As GADx's chief scientific officer, Paul leads the Centre for Advanced Rapid Diagnostics (CARD), funded by the Bill & Melinda Gates Foundation. Until 2002 he was as a senior scientist at Unilever Research, leading applied immunology, and is one of the inventors of the lateral flow immunoassay
Rwanda Boone - Chief Commercial Officer
Rwanda leads the commercial operation, focusing on bringing products to markets with various needs. Rwanda is a marketing strategist with extensive industry experience creating and implementing successful business initiatives. Her experience in the healthcare and medical device industry as a consultant and having led as Global Head of Customer & Commercial Excellence at Ascensia Diabetes Care and Head of Americas Brand Management at Bayer HealthCare.
Tim is a Chartered Biologist and a Fellow of the Royal Society of Biology and has over 19 years of experience leading the design and development diagnostic devices on multiple immunoassay platform technologies. Tim has made significant leadership and scientific contributions at AgPlus Diagnostics, Novartis, Vivacta, Oxonica and Oxford Immunotec where he was one of the original scientists responsible for the company's first product T-SPOT-TB™.